Furthermore, ibrutinib could inhibit malignant B cells homing to spleens and lymph nodes through reducing homing chemokines CXCR4, which resulted tumor cells moving into the circulation and are killed by CAR T cells (43). This evidence concerns the gene CXCR4 and neoplasm.